{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:32:01Z","timestamp":1793223121818,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-100002"],"award-info":[{"award-number":["DRCRPG-100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jbc.2026.113421","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:10:09Z","timestamp":1786342209000},"page":"113421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-0844","authenticated-orcid":false,"given":"Mahak","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-1058","authenticated-orcid":false,"given":"Stuart A.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipul R.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-2322","authenticated-orcid":false,"given":"Megan R.","family":"Chastney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-3277","authenticated-orcid":false,"given":"Matthew C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Warwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-7079","authenticated-orcid":false,"given":"Jonathan D.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-2807","authenticated-orcid":false,"given":"Benjamin T.","family":"Goult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-6967","authenticated-orcid":false,"given":"Martin J.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113421_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrgastro.2009.177","article-title":"Epidemiology of pancreatic cancer: an overview","volume":"6","author":"Raimondi","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jbc.2026.113421_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2011.40.1919","article-title":"Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"30","author":"Vogelzang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113421_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2017.01.002","article-title":"The cornerstone K-RAS mutation in pancreatic adenocarcinoma: from cell signaling network, target genes, biological processes to therapeutic targeting","volume":"111","author":"Jonckheere","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jbc.2026.113421_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"Pourshams","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jbc.2026.113421_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jbc.2026.113421_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.113421_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02787465","article-title":"Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine","volume":"22","author":"Rosenberg","year":"1997","journal-title":"Int. J. Pancreatol"},{"key":"10.1016\/j.jbc.2026.113421_bib8","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2009.21.9022","article-title":"Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment","volume":"27","author":"Philip","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113421_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","article-title":"Pancreatic cancer treatment: better, but a long way to go","volume":"50","author":"Torphy","year":"2020","journal-title":"Surg. Today"},{"key":"10.1016\/j.jbc.2026.113421_bib10","first-page":"2969","article-title":"Progression model for pancreatic cancer","volume":"6","author":"Hruban","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113421_bib11","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113421_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113421_bib13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.113421_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.biocel.2004.07.010","article-title":"Ductal cells of the pancreas","volume":"37","author":"Grapin-Botton","year":"2005","journal-title":"Int. J. Biochem. Cell Biol"},{"key":"10.1016\/j.jbc.2026.113421_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants","volume":"277","author":"Scheffzek","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jbc.2026.113421_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920211794520132","article-title":"Genetic and epigenetic alterations in pancreatic carcinogenesis","volume":"12","author":"Delpu","year":"2011","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.jbc.2026.113421_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113421_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.11.012","article-title":"Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities","volume":"54","author":"Bournet","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2016.09.003","article-title":"KRAS-related proteins in pancreatic cancer","volume":"168","author":"Mann","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2026.113421_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: the devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib22","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.113421_bib23","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2026.113421_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jbc.2026.113421_bib25","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2026.113421_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.jbc.2026.113421_bib27","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1535-7163.MCT-22-0356","article-title":"The next generation of KRAS targeting: reasons for excitement and concern","volume":"21","author":"Akhave","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2026.113421_bib28","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113421_bib29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gutjnl-2018-316822","article-title":"Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine","volume":"68","author":"Conway","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jbc.2026.113421_bib30","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004978","article-title":"The collagen family","volume":"3","author":"Ricard-Blum","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180181","article-title":"The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma","volume":"12","author":"Begum","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113421_bib32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bjc.2013.706","article-title":"Pancreatic stellate cells promote hapto-migration of cancer cells through collagen I-mediated signalling pathway","volume":"110","author":"Lu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib33","first-page":"5403","article-title":"High beta integrin expression is differentially associated with worsened pancreatic ductal adenocarcinoma outcomes","volume":"12","author":"Benesch","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113421_bib34","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41388-020-01594-4","article-title":"C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin \u03b1v","volume":"40","author":"Kuo","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2026.113421_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/cancers15030628","article-title":"Prognostic significance of integrin subunit alpha 2 (ITGA2) and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC)","volume":"15","author":"Gregori","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2026.113421_bib36","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3390\/cancers14143377","article-title":"Integrin \u03b21 in pancreatic cancer: expressions, functions, and clinical implications","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2026.113421_bib37","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1007\/s13277-015-4353-7","article-title":"Integrin \u03b26 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)","volume":"37","author":"Li","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.cgh.2008.05.006","article-title":"The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma","volume":"6","author":"Erkan","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jbc.2026.113421_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jbc.2026.113421_bib48","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1038\/s41467-018-05692-6","article-title":"Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability","volume":"9","author":"Adhikari","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113421_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.21873\/cgp.20034","article-title":"Analysis of K-Ras interactions by biotin ligase tagging","volume":"14","author":"Ritchie","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.jbc.2026.113421_bib55","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/s41596-019-0160-8","article-title":"High-resolution 3D imaging of fixed and cleared organoids","volume":"14","author":"Dekkers","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbc.2026.113421_bib56","doi-asserted-by":"crossref","first-page":"D115","DOI":"10.1093\/nar\/gkh131","article-title":"UniProt: the universal protein knowledgebase","volume":"32","author":"Apweiler","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbc.2026.113421_bib40","doi-asserted-by":"crossref","first-page":"43830","DOI":"10.1074\/jbc.M207221200","article-title":"Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway","volume":"277","author":"Steinle","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113421_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14646","article-title":"Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion","volume":"8","author":"Gundry","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113421_bib42","first-page":"305","article-title":"Normal epithelial cells trigger EphA2-dependent RasV12 cell repulsion at the single cell level","volume":"10","author":"Hill","year":"2019","journal-title":"Small GTPases"},{"key":"10.1016\/j.jbc.2026.113421_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/tra.12123","article-title":"EphA2 signaling following endocytosis: role of Tiam1","volume":"14","author":"Boissier","year":"2013","journal-title":"Traffic"},{"key":"10.1016\/j.jbc.2026.113421_bib45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cellsig.2016.04.009","article-title":"EphA2 is a key effector of the MEK\/ERK\/RSK pathway regulating glioblastoma cell proliferation","volume":"28","author":"Hamaoka","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.jbc.2026.113421_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2021.09.001","article-title":"EphA2 signaling within integrin adhesions regulates fibrillar adhesion elongation and fibronectin deposition","volume":"103-104","author":"Finney","year":"2021","journal-title":"Matrix Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib47","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/pr060630l","article-title":"An experimentally derived database of candidate Ras-interacting proteins","volume":"6","author":"Goldfinger","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jbc.2026.113421_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113326","article-title":"Proximal protein interaction landscape of RAS paralogs","volume":"12","author":"B\u00e9ganton","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2026.113421_bib50","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1038\/s41467-019-13106-4","article-title":"KRAS regulation by small non-coding RNAs and SNARE proteins","volume":"10","author":"Che","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113421_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2016904118","article-title":"Oncogenic KRAS engages an RSK1\/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer","volume":"118","author":"Cheng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.jbc.2026.113421_bib52","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2016.01.034","article-title":"KRAS engages AGO2 to enhance cellular transformation","volume":"14","author":"Shankar","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jbc.2026.113421_bib53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.molcel.2018.12.001","article-title":"The functional proximal proteome of oncogenic ras includes mTORC2","volume":"73","author":"Kovalski","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2026.113421_bib60","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1128\/MCB.21.21.7429-7441.2001","article-title":"Downregulation of the Ras\u2013mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction","volume":"21","author":"Elowe","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","article-title":"A conditional feedback loop regulates Ras activity through EphA2","volume":"8","author":"Macrae","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113421_bib62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer","volume":"99","author":"Chang","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib63","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000547","article-title":"Nuclear lamins","volume":"2","author":"Dechat","year":"2010","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib64","doi-asserted-by":"crossref","first-page":"OF16","DOI":"10.1158\/2159-8290.CD-RW2013-154","article-title":"SHC1 temporally regulates EGFR signaling","volume":"3","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbc.2026.113421_bib65","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/s41467-021-23053-8","article-title":"Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.113421_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3599832","article-title":"SHC1 promotes lung cancer metastasis by interacting with EGFR","volume":"2022","author":"Yang","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.jbc.2026.113421_bib67","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/373573a0","article-title":"Protein modules and signalling networks","volume":"373","author":"Pawson","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113421_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0092-8674(03)01077-8","article-title":"Specificity in signal transduction: from Phosphotyrosine-SH2 domain interactions to complex cellular systems","volume":"116","author":"Pawson","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.113421_bib69","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/0008-5472.CAN-12-4178","article-title":"The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression","volume":"73","author":"Ahn","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113421_bib70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nature12308","article-title":"Temporal regulation of EGF signalling networks by the scaffold protein Shc1","volume":"499","author":"Zheng","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.113421_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41563-021-01085-1","article-title":"A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids","volume":"21","author":"Below","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jbc.2026.113421_bib72","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1158\/0008-5472.CAN-05-2804","article-title":"Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells","volume":"66","author":"Koenig","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113421_bib73","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12253-009-9221-6","article-title":"Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma","volume":"16","author":"Giaginis","year":"2010","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.jbc.2026.113421_bib74","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/ijc.25942","article-title":"Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis","volume":"129","author":"Grzesiak","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113421_bib75","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1535-7163.MCT-18-0852","article-title":"SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors","volume":"18","author":"Lu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2026.113421_bib76","first-page":"1901","article-title":"Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jbc.2026.113421_bib77","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1074\/mcp.M116.058313","article-title":"Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling","volume":"15","author":"Humphrey","year":"2016","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.jbc.2026.113421_bib78","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3892\/ol.2012.650","article-title":"Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer","volume":"3","author":"Lu","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbc.2026.113421_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108765","article-title":"Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1\/STAT3 and AKT signaling","volume":"34","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2026.113421_bib80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41401-019-0268-y","article-title":"EPHA2 feedback activation limits the response to PDE\u03b4 inhibition in KRAS-dependent cancer cells","volume":"41","author":"Chen","year":"2020","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.jbc.2026.113421_bib81","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.cub.2016.09.037","article-title":"EphA2 drives the segregation of ras-transformed epithelial cells from normal neighbors","volume":"26","author":"Porazinski","year":"2016","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib82","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.cub.2021.03.094","article-title":"EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas","volume":"31","author":"Hill","year":"2021","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2026.113421_bib83","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0092-8674(00)81392-6","article-title":"The adaptor protein Shc couples a class of integrins to the control of cell cycle progression","volume":"87","author":"Wary","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.113421_bib84","article-title":"Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically \u2018actionable\u2019 signalling axis in triple negative breast cancer","author":"Yang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2026.113421_bib57","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbc.2026.113421_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jprot.2013.10.023","article-title":"SAINTexpress: improvements and additional features in significance analysis of INTeractome software","volume":"100","author":"Teo","year":"2014","journal-title":"J. Proteomics"},{"key":"10.1016\/j.jbc.2026.113421_bib59","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2021","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826022933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826022933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:34:28Z","timestamp":1793219668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826022933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0021925826022933"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113421","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113421"}}